Sprint Bioscience AB (publ) (FRA:5JA1)

Market Cap	30.49M +431.4%
Revenue (ttm)	12.55M +145.7%
Net Income	6.83M
EPS	0.06
Shares Out	n/a
PE Ratio	4.46
Forward PE	11.03
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.2690
Previous Close	0.2650
Day's Range	0.2690 - 0.2690
52-Week Range	0.0306 - 0.3850
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 2, 2026

About Sprint Bioscience AB

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of drug candidates to treat cancer in Sweden. The company develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; DCPS which is in preclinical trial for the treatment of acute myeloid leukemia; VRK1, which is in preclinical development to treat solid tumors; VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and NNMT for the treatment of solid tumors/chronic kidney diseases...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2009
• Employees: 30
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5JA1

Financial Performance

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error